NeuroFrontiers-logo

NeuroFrontiers

ReachMD

Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health. So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.

Location:

United States

Networks:

ReachMD

Description:

Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health. So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.

Language:

English


Episodes

Exploring the Clinical Treatments of Schizophrenia

3/27/2024
Host: Ashley Baker, MSN, PMHNP Guest: Nabil Ali, MD When it comes to treating patients with schizophrenia, it’s important to remember to not have one particular medication that you stick by at all times and to consider things like their personal history and their side effects. To learn more about the treatment algorithm when managing these patients, join in with Psychiatric Nurse Practitioner Ashley Baker as she speaks with Dr. Nabil Ali, Assistant Consulting Professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine in Durham, North Carolina.

Duration:00:12:00

The Role of Occupational Therapy in Schizophrenia Management

3/26/2024
Host: Ashley Baker, MSN, PMHNP Guest: Lauren Walker, OT Occupational therapists (OT) play a crucial role in the management of schizophrenia by focusing on enhancing the patient’s ability to engage in meaningful activities and daily life tasks. Working towards a goal that a patient has by breaking it down into smaller parts is one of the ways to help a patient be successful and spark motivation. Dive in further on how OT’s assist patients through first-episode psychosis and subsequent life changes with Psychiatric Nurse Practitioner Ashley Baker as she speaks with Lauren Walker, Occupational Therapist at Northwestern Feinberg School of Medicine.

Duration:00:09:53

Investigating the Prevalence of Comorbidities in MS Clinical Trials

3/22/2024
Host: Ashley Baker, MSN, PMHNP Guest: Amber Salter, PhD In 2016, an International Advisory Committee on Clinical Trials in Multiple Sclerosis (MS) recommended that comorbidities be more clearly and consistently described in enrolled clinical trial populations for common comorbidities so we can better understand the applicability of these trial findings to those in clinical practice. And so a recent study investigated the prevalence of comorbidities in MS clinical trial populations and found that 46 percent of the participants had one or more comorbid condition. Dive further into the findings from the study that was presented at the 2023 joint ECTRIMS-ACTRIMS meeting with Ashley Baker and Dr. Amber Salter, Associate Professor of Biostatistics at the University of Texas Southwestern Medical Center.

Duration:00:08:27

Assessing Disability in MS Patients with the SNRS and CombiWISE Tools

3/18/2024
Host: Andrew Wilner, MD, FACP, FAAN Guest: Dejan Jakimovski, MD, PhD Despite the fact that categorial scores like the Expanded Disability Status Scale (EDSS) and the MS Severity Scale (MSSS) are considered to be the gold standard, a recent study found that the Scripps Neurological Rating Scale (SNRS) and the Combinatorial Weight-Adjusted Disability Score (CombiWISE) may be better suited for assessing disability in patients who are severely affected by MS. Learn more about this study’s findings with Dr. Andrew Wilner and Dr. Dejan Jakimovski, a Research Assistant Professor in the Department of Neurology at the University of Buffalo who presented this research at the joint 2023 ECTRIMS-ACTRIMS meeting.

Duration:00:11:42

Disparities in DMT Access: Women with MS Are Less Likely to Receive Treatment

3/18/2024
Host: Andrew Wilner, MD, FACP, FAAN Guest: Victoria Leavitt, PhD Disease-modifying therapies (DMTs) are an effective option for patients with multiple sclerosis (MS). In fact, a recent study presented at the 2023 joint ECTRIMS-ACTRIMS meeting in Italy found that MS patients being treated with a DMT had better cognitive function than those who were not. However, the same study also found that women are less likely than men to receive DMT treatment. Dive further into the findings with Dr. Andrew Wilner and Dr. Victoria Leavitt, Assistant Professor of Neuropsychology at Columbia University.

Duration:00:12:18

Practices for Preventing Polypharmacy in Multiple Sclerosis

3/13/2024
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Ahmed Zayed Obeidat, MD, PhD Guest: Lauren Beranek, BS Polypharmacy is defined as the regular use of five or more prescribed medications, and due to their disease course, related symptoms, and side effects, patients with multiple sclerosis are at an increased risk of polypharmacy. So to hear insights on ways to identify, manage, and prevent polypharmacy, Dr. Mary Catherine Cheeley is joined by Dr. Ahmed Obeidat, Associate Professor of Neurology, and Lauren Beranek, MD candidate at the Medical College of Wisconsin. Find a full article on their findings published in Practical Neurology.

Duration:00:12:16

Understanding the Cellular Basis for Altered Cognition in Schizophrenia

3/13/2024
Host: Ashley Baker, MSN, PMHNP Guest: Samuel Dienel, PhD Using postmortem brain tissue, a recent study investigated how alterations in somatostatin messenger RNA levels in the dorsolateral prefrontal cortex affect cognition among individuals with schizophrenia, bipolar disorder, and major depressive disorder. Dive into the findings with psychiatric nurse practitioner Ashley Baker and Dr. Samuel Dienel, a student in the Medical Scientist Training Program at the University of Pittsburgh.

Duration:00:08:01

From Assessment to Management: Tackling Catatonia in Schizophrenic Patients

3/12/2024
Host: Ashley Baker, MSN, PMHNP Guest: Stanley N. Caroff, MD Catatonia is a neuropsychiatric condition characterized by disturbances in psychomotor function, stemming from various disorders impacting brain function. And while catatonia is not specifically related to schizophrenia alone, it’s important to know how to recognize and treat schizophrenic patients with catatonic symptoms. That’s why psychiatric nurse practitioner Ashley Baker speaks with Dr. Stanley Caroff about his research focusing on the management of schizophrenia with catatonic symptoms. Dr. Caroff is an Emeritus Professor of Psychiatry at the University of Pennsylvania Perelman School of Medicine.

Duration:00:13:12

How Alzheimer's and Lewy Body Pathology Impact CAA Risk Factors

3/7/2024
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jagan Pillai, MD, PhD Cerebral amyloid angiopathy (CAA) is a common neurological change that frequently coexists with other pathologies like Alzheimer's disease and Lewy body dementia, which led a team of researchers to investigate the risk factors and prevalence of CAA. The study found that not only is age a risk factor for CAA, but CAA is also seen in patients with Lew body pathology alone and in patients with both Alzheimer's disease and Lewy body pathology. Dive further into the findings with Dr. Charles Turck and Dr. Jagan Pillai, a behavioral neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health.

Duration:00:06:39

Exploring the Latest in MS Cognitive Rehabilitation Strategies

3/6/2024
Guest: Nancy Chiaravalloti, PhD Cognitive rehabilitation in patients with multiple sclerosis started about 20 to 25 years ago when it transitioned from predominantly patients with traumatic brain injury to other patient populations including multiple sclerosis. And over that period of time, the number of studies that have examined the efficacy of cognitive rehabilitation in MS has grown substantially. However, gaps remain and further research is needed. Dive into to learn more about cognitive rehabilitation trials for MS with Dr. Nancy Chiaravalloti, Director of the Center for Neuropsychology and Neuroscience Research and the Center for Traumatic Brain Injury Research at Kessler Foundation, who also presented a session on this topic at the ACTRIMS 2024 Forum.

Duration:00:05:14

Visionary Insights: Assessing MS-Related Retinal Changes with Adaptive Optics

3/4/2024
Guest: Daniel Harrison, MD Adaptive optics is a promising tool for studying MS-related changes in the retina at a cellular level, providing valuable insights into the disease's progression and potential treatments. Dive further into this line of research with Dr. Daniel Harrison, an Associate Professor of Neurology and the Director of the Division of Multiple Sclerosis and Neuroimmunology at the University of Maryland who presented this research at the 2024 ACTRIMS Forum.

Duration:00:07:14

Family Planning Clinical Considerations for Patients with Multiple Sclerosis

3/4/2024
Host: Ashley Baker, MSN, PMHNP Guest: Anna Shah, MD The prevalence of multiple sclerosis seems to be increasing in patients, and the majority of those patients are diagnosed with MS around the peak family planning age. So family planning should be an integral part of comprehensive patient-centered MS care. Learn more with Psychiatric Nurse Practitioner Ashey Baker as she speaks with Dr. Anna Shah, Assistant Professor of Neurology and the Director of Neurology Outpatient Patient Safety & Experience at the University of Colorado Anschutz School of Medicine.

Duration:00:14:36

Unmet Needs in Rehabilitation Research for Multiple Sclerosis

3/2/2024
Guest: Robert Motl, PhD Rehabilitation training for multiple sclerosis patients aims to improve mobility, cognitive function, and quality of life. But one of the largest barriers to having more high-quality randomized control trials of rehabilitation in MS is that most researchers could not be following a stage of different research approaches. So addressing the unmet needs in rehabilitation research is needed to make MS interventions more powerful. You’ll learn more in this episode with Dr. Robert Motl, Professor in the Department of Kinesiology and Nutrition with a secondary appointment in the Department of Rehabilitation Sciences at the University of Illinois Chicago.

Duration:00:05:42

Telehealth in MS Care: Addressing the Potential for Improvement and Concerns

2/28/2024
Guest: Marisa McGinley, DO The amount of patients being diagnosed with neurological conditions and multiple sclerosis (MS) is a growing number, which causes a need for more neurologists, MS specialists, and better access to care. A potential advantage of using technology in MS care would be to break down the geographic barrier. To learn more about telehealth in MS care, tune in with Dr. Marisa McGinley, Assistant Professor of Neurology at the Cleveland Clinic Lerner College of Medicine, who also presented this topic at the ACTRIMS Forum 2024.

Duration:00:05:20

MS Research: Using Epigenetic Clocks and Biomarkers to Assess Biological Aging

2/28/2024
Guest: Yinan Zhang, MD Chronological age is the biggest early driver of disease progression in patients with multiple sclerosis (MS). That’s why a team of researchers wanted to explore whether biomarkers like p16 and the epigenetic clock can be used to assess biological aging in patients with MS. They found that while patients with MS are aging faster than people without MS based on the epigenetic clock biomarker, no chronological age correlation in p16 expression has been identified in patients with MS. Dive further into these findings with Dr. Yinan Zhang, an Assistant Professor of Neurology at Ohio State University who presented this research at the 2024 ACTRIMS Forum.

Duration:00:05:04

Toxic Short RNAs May Cause Neuronal Cell Death in Alzheimer’s Disease

2/26/2024
Host: Andrew Wilner, MD, FACP, FAAN Guest: Marcus E. Peter, PhD Death induced by survival gene elimination (DISE) is a cell death mechanism mediated by short RNAs. And according to a recent study, there may be a correlation between toxic DISE, DNA damage, and neuronal cell death in patients with Alzheimer’s disease. Learn more about the study’s findings and potential implications with Dr. Andrew Wilner and Dr. Marcus Peter, Professor of Medicine in the Division of Hematology and Oncology as well as a Professor of Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine in Chicago.

Duration:00:09:39

Schizophrenia Diagnosis: The Importance of a Collaborative Approach

2/13/2024
Host: Ashley Baker, MSN, PMHNP Guest: Morris Goldman, MD Guest: Dara Sanandaji A diagnosis of schizophrenia can be distressing, making clinical interventions crucial for both the patient and their family. With the assistance of an appropriate treatment plan and peer support, the patient can gain empowerment to take control of their life and pursue long-term goals. Joining Psychiatric Nurse Practitioner Ashley Baker to discuss next steps following a schizophrenia diagnosis is Dr. Morris Goldman, Associate Professor of Psychiatry at Northwestern Feinberg School of Medicine, and Dara Sanandaji, Peer Support Supervisor at the Recovery from Early Psychosis Program.

Duration:00:10:02

Examining the Role of Toxic Tau Proteins in Alzheimer's Disease

2/12/2024
Host: Andrew Wilner, MD, FACP, FAAN Guest: George Bloom, PhD Toxic tau protein refers to an aberrant form of the tau protein in the brain, commonly associated with Alzheimer's disease, where it forms tangles and disrupts normal cellular function, which contributes to cognitive decline and neuronal damage. To learn more about the role of toxic tau proteins in Alzheimer’s disease, tune in to hear Dr. Andrew Wilner speak with Dr. George Bloom, Professor of Biology, Cell Biology, and Neuroscience at the University of Virginia.

Duration:00:08:27

A Successful and Safe Stem Cell Therapy for Progressive MS

2/12/2024
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Stefano Pluchino, MD, PhD An international collaborative phase 1 study has shown that the injection of a specific form of stem cells into the brains of patients with progressive multiple sclerosis is safe and effective in preventing further brain damage. However, a different type of clinical trial is needed to address whether an advanced cell therapy made of brain-specific stem cells is indeed leading to amelioration of disease features. Take a deeper look into the findings from this study as Dr. Charles Turck speaks with the author of the study, Dr. Stefano Pluchino, Professor of Regenerative Neuroimmunology and Honorary Consultant in Neurology in the Department of Clinical Neurosciences at Cambridge University.

Duration:00:07:02

New Study Shows EBV-Specific T-Cells Contribute to MS Development

2/12/2024
Guest: J. William Lindsey Epstein-Barr virus (EBV) has long been associated with multiple sclerosis (MS), but a recent study from UTHealth Houston has shed light on its role in the development of MS. To learn more on what we know about EBV-specific T-cells, join Dr. J. William Lindsey, Senior Author of the study, titled UTHealth Houston Study: EBV-specific T-cells play key role in development of multiple sclerosis, and Professor in the Department of Neurology and Director of the Division of Multiple Sclerosis and Neuroimmunology with McGovern Medical School at UTHealth Houston.

Duration:00:04:57